150 related articles for article (PubMed ID: 35901599)
1. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.
Cai S; Lin X; Sun Y; Lin Z; Wang X; Lin N; Zhao X
Eur J Radiol; 2022 Sep; 154():110449. PubMed ID: 35901599
[TBL] [Abstract][Full Text] [Related]
2. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
[TBL] [Abstract][Full Text] [Related]
3. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure.
Liu C; Shen Z; Ma H; Wang X; Wang X; Liu K; Wang X; Zhu Q; Zhao X
Eur Radiol; 2022 May; 32(5):3006-3015. PubMed ID: 34989839
[TBL] [Abstract][Full Text] [Related]
4. The value of contrast-enhanced portal vein imaging at the hepatobiliary phase obtained with gadobenate dimeglumine for predicting decompensation and transplant-free survival in chronic liver disease.
Cai S; Lin N; Yang Y; Ma W; Wang Y; Lin X; Wang X; Zhao X
Eur Radiol; 2023 May; 33(5):3425-3434. PubMed ID: 36897349
[TBL] [Abstract][Full Text] [Related]
5. The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients.
Meng D; Liang C; Zheng Y; Wang X; Liu K; Lin Z; Zhu Q; Zhao X
Eur Radiol; 2022 Dec; 32(12):8608-8616. PubMed ID: 35639146
[TBL] [Abstract][Full Text] [Related]
6. Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI.
Rong D; Liu W; Kuang S; Xie S; Chen Z; Chen F; Xie Q; Luo Q; He B; Zhang Y; Deng Y; Yang H; Chen S; Wang J
Eur Radiol; 2021 Oct; 31(10):7584-7593. PubMed ID: 33860826
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
[TBL] [Abstract][Full Text] [Related]
8. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
[TBL] [Abstract][Full Text] [Related]
9. Prediction of post-hepatectomy liver failure using gadoxetic acid-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein invasion.
Tsujita Y; Sofue K; Komatsu S; Yamaguchi T; Ueshima E; Ueno Y; Kanda T; Okada T; Nogami M; Yamaguchi M; Tsurusaki M; Hori M; Fukumoto T; Murakami T
Eur J Radiol; 2020 Sep; 130():109189. PubMed ID: 32784077
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
[No Abstract] [Full Text] [Related]
11. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.
Park Y; Kim SH; Kim SH; Jeon YH; Lee J; Kim MJ; Choi D; Lee WJ; Kim H; Koo JH; Lim HK
Korean J Radiol; 2010; 11(4):433-40. PubMed ID: 20592927
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the cut-off value of quantitative liver-portal vein contrast ratio in the hepatobiliary phase of liver MRI.
Takatsu Y; Nakamura M; Shiozaki T; Narukami S; Yoshimaru D; Miyati T; Kobayashi S
Clin Radiol; 2021 Jul; 76(7):551.e17-551.e24. PubMed ID: 33902888
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
14. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas.
Kim YK; Kim CS; Lee YH; Kwak HS; Lee JM
AJR Am J Roentgenol; 2004 May; 182(5):1217-23. PubMed ID: 15100122
[TBL] [Abstract][Full Text] [Related]
15. Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure.
Zhu WS; Shi SY; Yang ZH; Song C; Shen J
World J Gastroenterol; 2020 Mar; 26(11):1208-1220. PubMed ID: 32231424
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.
Stocker D; Hectors S; Bane O; Vietti-Violi N; Said D; Kennedy P; Cuevas J; Cunha GM; Sirlin CB; Fowler KJ; Lewis S; Taouli B
Eur Radiol; 2021 Dec; 31(12):9306-9315. PubMed ID: 34043055
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
[TBL] [Abstract][Full Text] [Related]
18. Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.
Liu C; Sun Y; Yang Y; Feng Y; Xie X; Qi L; Liu K; Wang X; Zhu Q; Zhao X
Eur Radiol; 2021 Aug; 31(8):5840-5850. PubMed ID: 33533990
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular Carcinoma: Retrospective Evaluation of the Correlation Between Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Pathologic Grade.
Huang X; Xiao Z; Zhang Y; Lin N; Xiong M; Huang X; Chen Q; Cao D
J Comput Assist Tomogr; 2018; 42(3):365-372. PubMed ID: 29369947
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
